Abstract:Abstract Introduction: BRCA1 mutant cancers are defective for homologous recombination (HR) and as a result are highly sensitive to PARP inhibitor (PARPi) therapy. HR is initiated by DNA end resection, followed by the loading of RAD51 onto resected DNA. 53BP1 blocks DNA end resection and consequently prevents HR. In contrast, BRCA1 promotes DNA end resection, possibly by displacing 53BP1 from double-stranded DNA breaks. BRCA1 also contributes to HR downstream of DNA end resection by directly interacting with PALB2 and forming a larger BRCA1-PALB2-BRCA2-RAD51 complex that promotes RAD51 loading. In the absence of BRCA1, genetic disruption of 53BP1 has been shown to activate DNA end resection and restore HR, resulting in PARPi resistance. Despite clear evidence of activated DNA end resection, the efficiency of RAD51 loading and overall HR in the absence of BRCA1 and 53BP1 is unclear, and may be dependent on specific BRCA1 mutations that are present in a given cell line or mouse model. Experimental Procedures: We investigated the impact of BRCA1 mutations on 53BP1-mediated restoration of HR and PARPi resistance. SUM149PT, UWB1.289, L56-BRC1 cell lines have BRCA1 exon 11 mutations and express the hypomorphic BRCA1-Δ11q splice variant; whereas MDA-MB-436, HCC1395 and SUM1315MO2 harbor RING or BRCT domain mutations and have undetectable truncated BRCA1 protein expression. We used CRISPR/Cas9 to generate a Brca11361fsX allele that was crossed with 53bp1-/- mice. Results: 53BP1-targeting shRNA provided dramatic PARPi rescue in SUM149PT, UWB1.289, L56-BRC1 cells, with rucaparib IC50 values ranging from 100 to 500 nM. In contrast, 53BP1 shRNA scarcely impacted MDA-MB-436, HCC1395, and SUM1315MO2 cells, with IC50 values ranging from 0.5 to 2 nM. A closer inspection of HR steps revealed that 53BP1 loss activated DNA end resection in all cell lines, measured using RPA32 foci. However, downstream of resection, RAD51 foci increased in SUM149PT, UWB1.289, L56-BRC1 cells, but remained low in MDA-MB-436, HCC1395, and SUM1315MO2 cells. Because the former cell lines express the BRCA1-Δ11q splice variant that retains the ability to interact with PALB2, we examined the impact of hypomorphic BRCA1 protein expression and the BRCA1-PALB2 interaction on 53BP1-mediated PARPi rescue. Exogenous expression of BRCA1-Δ11q, BRCA1-ΔRING, or BRCA1-ΔBRCT all dramatically enhanced 53BP1-mediated RAD51 foci and PARPi resistance in an isogenic MDA-MB-436 complementation system. However, when a BRCA1L1407P missense mutation was introduced that abrogates the BRCA1-PALB2 interaction, 53BP1-induced RAD51 loading and PARPi resistance was completely abolished. The Brca11361fsX allele has a stop codon prior to critical amino acids required for Brca1-Palb2 association and homozygosity results in embryonic lethality. In contrast to previous studies using hypomorphic Brca1 alleles, matings with 53bp1-/- mice did not rescue the embryonic viability of Brca11361fsX mice. Conclusions: These findings suggest that although 53BP1 loss of function is capable of promoting DNA end resection, efficient RAD51 loading remains dependent on BRCA1 and intact BRCA1-PALB2 complexes. Patients with BRCA1 mutations that prevent BRCA1-PALB2 association may have prolonged responses to PARPi therapy and are unlikely to succumb to 53BP1-loss of function-driven resistance. Citation Format: Joseph Nacson, Andrea Bernhardy, Xiang Hua, Yifan Wang, John Krais, Neil Johnson. 53BP1-driven homologous recombination and PARP inhibitor resistance requires intact BRCA1-PALB2 association. [abstract]. In: Proceedings of the AACR Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment; Oct 1-4, 2017; Pittsburgh, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(15_Suppl):Abstract nr A07.

Abstract 5608: The BRCA1-associated role of CDK9 in response to DNA damage is independent of its canonical role in transcription

Abstract C102: mRNA-mediated restoration of BRCA-1 tumor suppressor function prevents tumor growth and reverses resistance to PARP inhibitors in triple-negative breast cancers

Abstract A07: 53Bp1-Driven Homologous Recombination and PARP Inhibitor Resistance Requires Intact BRCA1-PALB2 Association

Abstract 216: Expression of DNA damage response proteins modifies the efficacy of CDK4/6 inhibitor-mediated radiosensitization in breast cancer models

Abstract IA014: BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair

Author Correction: the Bromodomain Containing Protein BRD-9 Orchestrates RAD51–RAD54 Complex Formation and Regulates Homologous Recombination-Mediated Repair

Abstract B011: CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway by affecting the UFL1 ubiquitination

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Abstract 3908: DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2

BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage

Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2

CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway choice

Abstract 994: Long Noncoding RNAs Generated from the BRCA1 Pseudogene Regulate Genomic Instability and Homologous Recombination Repair

Abstract 5606: The role of KMT2C in the homologous recombination repair in epithelial ovarian cancer

Abstract B019: Deciphering the role of homologous recombination deficiency mutations in the response to combined immune checkpoint and PARP inhibitors

Abstract 3669: “DNA Binding Region” of BRCA1 Affects Genetic Stability Through Modulating the Intra-S-phase Checkpoint

Abstract A050: CD8+ T cell exhaustion and their DNA damage in BRCA1 mutated TNBC

Abstract 6096: BRCA1-BARD1 ubiquitylates histones for genome maintenance

Abstract #4440: BRCA1 Modulates Malignant Cell Behavior, the Expression of Survivin and Chemosensitivity in Human Breast Cancer Cells

Abstract 1218: CDK9 inhibitors modulate the transcriptional landscape of colorectal cancer to suppress MAPK signaling and synergizes with BRAF inhibitors to treat BRAF-mutant colorectal cancer

Abstract PO1-13-11: ZNF689 Promotes Homologous Recombination Via NBS1 Ubiquitination and Its Loss Confers Sensitivity to PARP Inhibition in Triple-Negative Breast Cancer